3D Cell Culture Market (2023-2030)
The 3D Cell Culture Market is projected to reach $4.02 billion by 2030, at a CAGR of 15.1% from 2023 to 2030. 3D cell culture is an environment that allows cells to grow and interact in three dimensions with the extracellular matrix.
- Published
- Jul 2023
- Pages
- 210
- Format
- PDF + Excel
- Report ID
- MRHC - 104159
- Base year
- 2022
- 2030 · FORECAST
- $4.02B
- 2030
- $4.02B
- CAGR 2023–2030
- 15.1%
2022 baseline · 2023–2030 forecast at 15.1% CAGR · hover a bar for the value
Key highlights
In 2023, the Scaffold-based Segment is Expected to Account for the Largest Share of the Market
In 2023, the Cancer Research Segment is Expected to Account for the Largest Share of the Market
In 2023, the Pharmaceutical and Biotechnology Companies Segment is Expected to Account for the Largest Share of the Market
Asia-Pacific: Fastest-growing Regional Market
Report summary
| Particulars | Details |
|---|---|
| Page No | ~210 |
| Format | |
| Forecast Period | 2023-2030 |
| Base Year | 2022 |
| CAGR | 15.1% |
| Market Size (Value) | $4.02 billion by 2031 |
| Segments Covered | By Product · Scaffold-free platforms · Low Attachment Surfaces · Hanging Drop Method · Micro-patterned surfaces · Rotating bioreactors · Magnetic 3D Bioprinting · Scaffold-based platforms · Hydrogels · Porous Scaffolds · Fibrous Scaffolds · Other Scaffold-based platforms · Accessories and Consumables · Other Products · (Notes:1. Other scaffold-based platforms include solid scaffolds and non-gel polymer scaffolds) · Note 2. Other products include 3D petridishes & microchips)) · By Application · Cancer Research · Regenerative Medicines · Drug Discovery and Testing · Tissue Engineering · Other Applications · (Note: Other applications include toxicology and disease modeling.) · By End User · Pharmaceutical and Biotechnology Companies · Academic and Research Institutes · Cosmetic Companies · Contract Research Organisations |
| Countries Covered | North America (U.S., Canada), Europe (Germany, France, U.K., Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of APAC), Latin America (Brazil, Mexico, Rest of Latin America), and Middle East & Africa |
| Key Companies | Thermo Fisher Scientific (U.S.), Merck KGaA (Germany), Lonza Group AG (Switzerland), Corning Incorporated (U.S.), UPM-Kymmene Corporation (Finland), REPROCELL Inc. (Japan), SYNTHECON, INCORPORATED (South Africa), InSphero AG (Switzerland ), Advanced BioMatrix (U.S.), MIMETAS B.V. (Netherlands), and Greiner Bio-One International GmbH (Austria). |
Report overview
Segments covered: product, application. Regions: North America, Europe, Asia-Pacific, Latin America.
In comparison, traditional 2D cell cultures involve cells growing as a flat monolayer on a plate. 3D cell culture models can be scaffold-based or scaffold-free. 3D cell culture or 3D tissue cell culture has enabled researchers to study various aspects of cell behavior, including cell morphology, differentiation, proliferation, invasion, migration, protein synthesis, and gene expression.
3D cell culture and 3D cell models play a crucial role in understanding disease mechanisms. They involve creating 3D culture systems, such as cancer organoids, derived directly from patient samples. These 3D culture systems can be used to study disease pathways by altering genes and screening small-molecule medicines. Compared to 2D cell cultures, 3D cell cultures provide more accurate predictions of toxicity and efficacy in drug treatments.
This market's growth is driven by increasing cancer research, the growing use of 3D cell culture in drug discovery and toxicology testing, the high demand for organ transplants, rising investments and funding for life science research, and the utilization of 3D cell culture models in animal testing. Additionally, emerging economies and a growing focus on regenerative medicine are expected to offer significant market growth opportunities.
However, the high cost associated with cell biology research and the shortage of skilled professionals in the field restrains the growth of this market. Additionally, the lack of consistency in 3D cell culture products poses a significant challenge to the market's growth.
Report infographic
Market dynamics
1 factors across 1 forceHigh Growth Prospects in Emerging Economies to Offer Market Growth Opportunities
Developed economies, including the U.S. and European countries, have been driving the growth of the 3D cell culture market. These markets have relatively higher levels of adoption and penetration of advanced technologies. As a result, companies operating in the 3D cell culture market are increasingly turning their attention to untapped potential in emerging economies.
Emerging countries in Asia and Latin America, such as India, China, Brazil, and Singapore, present significant growth opportunities for the 3D cell culture market. These countries are experiencing notable improvements in their healthcare infrastructures, making healthcare services more accessible to a broader population. Additionally, there is a high demand for organ transplants in these countries, further boosting the need for advanced technologies like 3D cell culture to support transplantation procedures.
According to the Organization for Economic Cooperation and Development (OECD), per capita health expenditure in developing countries is rising steadily. This rise in health expenditure can be attributed to the increasing demand for advanced research in critical areas such as cancer, regenerative medicine, and drug discovery, which supports the growth of the 3D cell culture market. Furthermore, economic development and higher disposable income, along with improved access to healthcare services through health insurance, are fueling the growth of the 3D cell culture market in these countries. According to the World Health Organization’s 2021 report, government health spending increased from 11.9% to 15.0% in 2020. In addition, according to global Economic Data, Indicators, Charts & Forecasts (CEIC) Data, the per capita disposable income in China was $5,444.8 million (¥35.1 million) in 2021 and $5,480.5million (¥36.8 million) in 2022, an increase of 2.6%.
The increasing prevalence of cancer in developing countries, including India, China, and Brazil, is driving the demand for cancer research, regenerative medicines, and novel therapies. According to GLOBOCAN, in 2020, 1.3 million new cancer cases were detected in India, and it is expected to increase to 1.7 million by 2030. Furthermore, in China, 54,227 new cancer cases were detected in 2020. It is expected to increase to 71,139 by 2030. This growing cancer prevalence has led to increased research efforts to develop regenerative medicines and therapies, subsequently driving the demand for 3D cell culture. Additionally, the improving accessibility and affordability of healthcare services in these regions further contribute to the rising demand for 3D cell culture.
Table of contents
11 chapters · 100 sections · 210 pages · click to expandSegmental analysis
| Segment | Largest share (2023) | Fastest growth (2023–2030) |
|---|---|---|
| By Product | Scaffold-based | — |
| By Application | Cancer Research | — |
| By End User | Pharmaceutical and Biotechnology Companies | — |
By Product
- The scaffold-based segment is expected to account for the largest share of the 3D cell culture market.
- Scaffold-based methods are commonly used in 3D cell culture, where cells are grown with the support of a scaffold.
- The scaffold can be made of synthetic materials or extracellular matrix (ECM), which provides structural and mechanical support to the cells.
- The ECM offers essential properties such as elasticity and rigidity required for cell growth.
- Due to these advantages, scaffold-based techniques are widely preferred for 3D cell cultures.
By Application
- The cancer research segment is expected to account for the largest share of the 3D cell culture market.
- The large market share of this segment is attributed to the high prevalence of cancer, which necessitates the development of innovative therapies. 3D cell cultures play a significant role in cancer-related drug discovery, allowing for the study of cell morphology and drug modeling.
- According to GLOBOCAN 2020, there were 19.3 million new cancer cases in 2020, and this number is expected to reach 24.6 million by 2030.
- As a result, the increasing prevalence of cancer fuels research efforts for novel treatments, contributing to the dominant market share of the cancer research segment.
By End User
- The pharmaceutical and biotechnology companies segment is expected to account for the largest share of the 3D cell culture market.
- Pharmaceutical and biotechnology companies are extensively investing in R&D to launch innovative therapies.
- According to data released by Creative Biolabs, Inc., a U.S.-based life sciences company, as of April 16, 2021, the number of active cell therapies for cancer was reported to be 2,073 in the global pipeline, an increase of 572 compared to 2020.
- In addition, collaborations between pharmaceutical companies and 3D cell culture providers are becoming more prevalent, facilitating research and drug development advancements.
- For instance, in February 2020, zPREDICTA, Inc. (U.S.) collaborated with Laboratory Corporation of America Holdings (U.S.) to advance the use of 3D cell cultures in research and drug development.
- As a result, the growing collaborations and the focus on developing innovative therapies by pharmaceutical companies contribute to the large market share of this segment in the 3D cell culture market.
Geographic analysis
Asia-Pacific
Fastest growthThe growth of this regional market is attributed to the increasing incidence of cancer, the presence of key 3D cell culture companies in countries like China, India, Singapore, and South Korea, advancements in technology related to 3D cell culture, and government investments in research and development activities. Furthermore, the accessibility of private and public funding for the development of advanced 3D cell culture models contributes to the growth of this market. For instance, in December 2021, Inventia Life Science Pty Ltd. (Australia) invested $25 million to market the RASTRUM 3D cell culture platform globally. Asia-Pacific: Fastest-growing Regional Market
Competitive landscape
- Thermo Fisher Scientific (U.S.)
- Merck KGaA · Germany
- Lonza Group AG · Switzerland
- Corning Incorporated (U.S.)
- UPM-Kymmene Corporation · Finland
- REPROCELL Inc. · Japan
- SYNTHECON, INCORPORATED · South Africa
- InSphero AG · Switzerland
- Advanced BioMatrix (U.S.)
- MIMETAS B.V. · Netherlands
- Greiner Bio-One International GmbH · Austria
Frequently asked questions
This study offers a detailed assessment of the 3D cell culture market and analyzes the market sizes & forecasts based on product, application, and end user. This report also involves the value analysis of various segments and subsegments of the 3D cell culture market at the regional and country levels.
Cite this report
Meticulous Research. (2023). 3D Cell Culture Market - Global Opportunity Analysis and Industry Forecast (2023-2030) (Report No. MRHC - 104159). Meticulous Market Research Pvt. Ltd. https://www.meticulousresearch.com/product/3d-cell-culture-market-1246